Annual General Meeting 2026: Tecan proposes the election of three new members of the Board of Directors and a new Chairman Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot will be proposed as new members of the Board of DirectorsLukas Braunschweiler, Chairman, and Oliver Fetzer, member of the Board, will not be standing for re-election Board of Directors will propose re-election of four current membersMatthias Gillner, Vice-Chairman of the Board, will be proposed as the new ChairmanMyra Eskes, Chris ...

Core Insights - Tecan Group has announced a strategic collaboration with NVIDIA to enhance AI-enabled platforms for Data-Driven Laboratories, aiming for faster discoveries and increased lab productivity [1][3]. Group 1: Collaboration Details - The partnership focuses on integrating NVIDIA's GPU-accelerated models and libraries into Tecan's products to transform lab data into actionable insights [4]. - The collaboration aims to establish Data-Driven Labs, leveraging AI to unlock the potential of underutilized lab-generated data [3][5]. Group 2: Company Background - Tecan is a pioneer in laboratory automation, transitioning from manual to automated pipetting, and continues to innovate with products like the Introspect lab analytics platform [2]. - In 2025, Tecan reported sales of CHF 883 million (approximately USD 1,063 million) [6].

Core Insights - Tecan Group has announced a strategic collaboration with NVIDIA to enhance AI-enabled platforms for Data-Driven Laboratories, aiming for faster discoveries and increased lab productivity [1][3]. Group 1: Collaboration Details - The partnership focuses on integrating NVIDIA's GPU-accelerated models and libraries into Tecan's products, which will help convert lab data into actionable insights [4]. - The collaboration aims to establish Data-Driven Labs, leveraging AI to unlock the potential of underutilized lab-generated data [3][5]. Group 2: Company Background - Tecan is a pioneer in laboratory automation, transitioning from manual to automated pipetting, and continues to innovate with products like the Introspect lab analytics platform [2][6]. - In 2025, Tecan reported sales of CHF 883 million (approximately USD 1,063 million), highlighting its significant presence in the laboratory automation market [6]. Group 3: Future Opportunities - The collaboration is expected to drive the next lab revolution by enhancing productivity and enabling breakthrough discoveries through intelligent automation solutions [3][5]. - Tecan's CEO emphasized the transformational potential of AI in laboratory settings, indicating a strong alignment between Tecan's expertise and NVIDIA's advanced AI platforms [5].

Core Insights - Tecan reported a return to sales growth and strong order entry in the second half of 2025, with a focus on reigniting profitable growth through a transformation program [2][3][5] Financial Results - Total sales for 2025 were CHF 882.5 million, a decrease of 1.6% in local currencies and 5.5% in Swiss francs compared to 2024 [6][8] - Adjusted EBITDA was CHF 142.1 million, with an adjusted EBITDA margin of 16.1%, down from 17.6% in 2024, impacted by foreign exchange effects and tariffs [9] - The company reported a net loss of CHF 110.7 million due to non-cash impairment charges of CHF 139.5 million, compared to a net profit of CHF 67.7 million in 2024 [10] - Operating cash flow was CHF 138.0 million, with cash conversion improving to 118% of reported EBITDA [11] Order Entry and Sales - Order entry for 2025 reached CHF 900.9 million, declining by 0.3% in Swiss francs but growing by 3.8% in local currencies [7] - In the second half of 2025, order entry grew by 8.6% in local currencies [7] Business Segments - Life Sciences Business sales were CHF 377.1 million, down 1.0% in local currencies and 5.0% in Swiss francs, with demand impacted by budget uncertainty [13] - Partnering Business sales were CHF 505.4 million, representing a decrease of 2.0% in local currencies and 5.9% in Swiss francs [15] Outlook - For 2026, Tecan expects sales to increase in the low single-digit percentage range in local currencies, with market growth anticipated to remain broadly flat [21] - The adjusted EBITDA margin is forecasted to be between 15.5% and 16.5%, reflecting a headwind from foreign exchange and tariffs [22] - Tecan aims to achieve sales of CHF 1 billion and a 20% adjusted EBITDA margin by 2028, supported by the ongoing transformation program [23][24]

Core Viewpoint - Tecan Group will present its full-year 2025 financial results and provide a Capital Markets Update on March 16, 2026, at an Analyst and Media Conference in Zurich [1][2]. Group 1: Event Details - The Analyst and Media Conference will take place at Metropol Zurich on March 16, 2026, at 2:00 pm CET [1]. - The event will be audio-webcast with synchronized presentation slides, and in-person attendance requires prior registration due to limited capacity [2]. - A replay of the webcast will be available on Tecan's website for 12 months following the presentation [3]. Group 2: Company Overview - Tecan is a pioneer in laboratory automation and a global leader in developing and manufacturing OEM instruments, components, and medical devices [4]. - Founded in Switzerland in 1980, Tecan employs over 3,000 people and has manufacturing, research, and development sites in Europe, North America, and Asia [4]. - The company maintains a sales and service network in over 70 countries and is listed on the SIX Swiss Exchange under the ticker TECN [4].

Core Insights - Tecan reported a return to sales growth and strong order entry in the second half of 2025, with full-year sales in local currencies aligning with previous forecasts [1][2] Sales Performance - Group sales for 2025 decreased by 1.6% in local currencies and 5.5% in Swiss francs, totaling CHF 882.5 million compared to CHF 934.3 million in 2024 [2] - In the second half of 2025, Tecan experienced moderate sales growth, with a 0.4% increase in local currencies, while sales in Swiss francs declined by 5.2% to CHF 443.0 million [2] Order Entry - Full-year order entry reached CHF 900.9 million, a decline of 0.3% in Swiss francs but an increase of 3.8% in local currencies compared to 2024 [3] - In the second half of 2025, order entry grew by 8.6% in local currencies and by 2.6% in Swiss francs [3] Segment Sales - Life Sciences Business sales were CHF 377.1 million, down 1.0% in local currencies and 5.0% in Swiss francs [5] - Partnering Business recorded sales of CHF 505.4 million, representing a decrease of 2.0% in local currencies and 5.9% in Swiss francs [5] Profitability and Outlook - Tecan reaffirmed its adjusted EBITDA margin guidance for 2025, as previously announced [6] - The company anticipates a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, with gradual recovery expected in end markets [7]

Core Points - Tecan Group Ltd. will propose changes to shareholders at the Annual General Meeting on April 15, 2026, including the nomination of Gitte Pugholm Aabo as a new independent member of the Board of Directors [1][5] - Lukas Braunschweiler, the current Chairman of the Board, will not stand for re-election, and Matthias Gillner is proposed as the new Chairman [5] Company Overview - Tecan is a global leader in laboratory automation, founded in Switzerland in 1980, with over 3,000 employees and operations in Europe, North America, and Asia [3] - In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million) [3] - The company focuses on empowering healthcare innovation from life sciences to clinical applications [3] Board Member Qualifications - Gitte Pugholm Aabo has a strong financial background, having served as President and CEO of GN Store Nord's Hearing Business and held various roles at LEO Pharma [2][1] - Aabo is considered highly qualified to serve as a financial expert on the Board and is well-suited for membership in the Audit Committee [2]

Core Insights - Tecan Group has acquired Wako Automation assets, including the Director™ scheduling software and select hardware modules, completing the transaction on December 1, 2025 [1] - The acquisition aims to expand Tecan's market beyond liquid-handling products and enhance its leadership in laboratory automation [2] Group 1: Acquisition Details - The acquisition includes the flagship Director™ software and hardware, which will be integrated into Tecan Labwerx, enhancing custom lab automation solutions [4] - This move builds on Tecan's previous success with FlowPilot, a scheduling software for robotic workcells, which was initially licensed from Wako Automation [3] Group 2: Strategic Objectives - Tecan's strategic goal is to provide advanced scheduling software that allows customers to manage complex workflows with improved flexibility and efficiency [2] - The integration of Wako's scheduling software and hardware is expected to strengthen Tecan's offerings in the growing biopharma segment, where the Director software is already utilized by established clients [4][5] Group 3: Leadership and Market Position - Tecan's CEO, Monica Manotas, emphasized that the addition of Wako's expertise will accelerate the growth of Tecan's custom lab automation business, Labwerx [5] - Tecan is positioned to meet the increasing demand for flexible, scalable, and integrated automation solutions in the market [5]

Core Viewpoint - Tecan Group announces the departure of CFO Tania Micki, effective May 2026, to pursue an external opportunity, with a succession plan in place for her replacement [1]. Group 1: Management Changes - Tania Micki has been with Tecan since February 2020 and has significantly contributed to the company's financial strategy and operational excellence [2]. - The Board of Directors and CEO express gratitude for her commitment and contributions during her tenure [2]. Group 2: Company Overview - Tecan is a global leader in laboratory automation, founded in Switzerland in 1980, with over 3,000 employees and operations in Europe, North America, and Asia [3]. - In 2024, Tecan reported sales of CHF 934 million (approximately USD 1,062 million or EUR 984 million) [3].

Core Insights - Tecan reports mid-single-digit local currency growth in Q3 2025, confirming its full-year 2025 outlook despite previous declines in Q1 and Q2 [1][2][3] Financial Performance - Sales for Q3 2025 increased by a mid-single-digit percentage in local currencies, following a mid-single-digit decline in Q1 and a low-single-digit decline in Q2 [2] - The Life Sciences Business experienced a low-single-digit sales decline, while the Partnering Business achieved a sales increase in the low teens percentage range [2] - Order intake exceeded sales in Q3, maintaining a book-to-bill ratio above 1 [2] Full-Year Outlook - Tecan confirms its full-year sales outlook, expecting sales in local currencies to range from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating performance will be in the lower half of this range [3] - The adjusted EBITDA margin forecast for full-year 2025 is reiterated at 17.5% to 18.5% of sales [4] Impact of Tariffs and Exchange Rates - The estimated net impact on the adjusted EBITDA margin for 2025 could be around 100 basis points due to higher reciprocal tariff levels [5] - If the current US dollar to Swiss franc exchange rate persists, it may lead to an additional negative impact of approximately 100 basis points on the adjusted EBITDA margin [5] Mid-Term Outlook - Tecan maintains its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range under normal market conditions [6] - Full normalization of end markets is not expected until 2026, with guidance for 2026 to be provided alongside full-year 2025 results [6] Regional Performance - Sales in the US Academia & Government sector are trending toward the middle of the initially assumed range, while demand in China remains subdued [7] - Biopharma sales in the second half of 2025 are expected to align with stable sales development seen in the first half [7] - Newly launched products and growth segments are contributing positively, with sales to the largest Partnering Business customer expected to be stable compared to the prior year [7] Market Positioning - Tecan is well-positioned to benefit from robust underlying megatrends driving increased demand for healthcare solutions [8] - The company generated sales of CHF 934 million (USD 1,062 million; EUR 984 million) in 2024, with a global presence in over 70 countries [9]